Main Menu

Publications Highlights View all by category

Types of Publications

Journal Articles

Tajan, M. Hennequart, M. Cheung, E.C. Zani, F. Hock, A.K. Legrave, N. Maddocks, O.D. Ridgway, R.A. Athineos, D. Suárez-Bonnet, A. Ludwig, R.L. Novellasdemunt, L. Angelis, N. Li, V.S. Vlachogiannis, G. Valeri, N. Mainolfi, N. Suri, V. Friedman, A. Manfredi, M. Blyth, K. Sansom, O.J. Vousden, K.H. (2021). Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy. Nature communications, Vol.12 (1).  show abstract

Kühnl, A. Peckitt, C. Patel, B. Ardeshna, K.M. Macheta, M.P. Radford, J. Johnson, R. Paneesha, S. Barton, S. Chau, I. Begum, R. Valeri, N. Wotherspoon, A. Du, Y. Zerizer, I. Cunningham, D. (2020). R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial. Annals of hematology, Vol.99 (1), pp. 105-112.

Khakoo, S. Carter, P.D. Brown, G. Valeri, N. Picchia, S. Bali, M.A. Shaikh, R. Jones, T. Begum, R. Rana, I. Wotherspoon, A. Terlizzo, M. von Loga, K. Kalaitzaki, E. Saffery, C. Watkins, D. Tait, D. Chau, I. Starling, N. Hubank, M. Cunningham, D. (2020). MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer. Clinical cancer research, Vol.26 (1), pp. 183-192.

Fassan, M. Realdon, S. Cascione, L. Hahne, J.C. Munari, G. Guzzardo, V. Arcidiacono, D. Lampis, A. Brignola, S. Dal Santo, L. Agostini, M. Bracon, C. Maddalo, G. Scarpa, M. Farinati, F. Zaninotto, G. Valeri, N. Rugge, M. (2020). Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrett’s carcinogenesis. Pathology - research and practice, Vol.216 (5), pp. 152907-152907.

Ratti, M. Lampis, A. Ghidini, M. Salati, M. Mirchev, M.B. Valeri, N. Hahne, J.C. (2020). MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside. Targeted oncology, Vol.15 (3), pp. 261-278.

Loupakis, F. Depetris, I. Biason, P. Intini, R. Prete, A.A. Leone, F. Lombardi, P. Filippi, R. Spallanzani, A. Cascinu, S. Bonetti, L.R. Maddalena, G. Valeri, N. Sottoriva, A. Zapata, L. Salmaso, R. Munari, G. Rugge, M. Dei Tos, A.P. Golovato, J. Sanborn, J.Z. Nguyen, A. Schirripa, M. Zagonel, V. Lonardi, S. Fassan, M. (2020). Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. The oncologist, Vol.25 (6), pp. 481-487.

Amodio, V. Yaeger, R. Arcella, P. Cancelliere, C. Lamba, S. Lorenzato, A. Arena, S. Montone, M. Mussolin, B. Bian, Y. Whaley, A. Pinnelli, M. Murciano-Goroff, Y.R. Vakiani, E. Valeri, N. Liao, W.-. Bhalkikar, A. Thyparambil, S. Zhao, H.-. de Stanchina, E. Marsoni, S. Siena, S. Bertotti, A. Trusolino, L. Li, B.T. Rosen, N. Di Nicolantonio, F. Bardelli, A. Misale, S. (2020). EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. Cancer discovery, Vol.10 (8), pp. 1129-1139.

Carotenuto, P. Hedayat, S. Fassan, M. Cardinale, V. Lampis, A. Guzzardo, V. Vicentini, C. Scarpa, A. Cascione, L. Costantini, D. Carpino, G. Alvaro, D. Ghidini, M. Trevisani, F. Te Poele, R. Salati, M. Ventura, S. Vlachogiannis, G. Hahne, J.C. Boulter, L. Forbes, S.J. Guest, R.V. Cillo, U. Said‐Huntingford, I. Begum, R. Smyth, E. Michalarea, V. Cunningham, D. Rimassa, L. Santoro, A. Roncalli, M. Kirkin, V. Clarke, P. Workman, P. Valeri, N. Braconi, C. (2020). Modulation of Biliary Cancer Chemo‐Resistance Through MicroRNA‐Mediated Rewiring of the Expansion of CD133+ Cells. Hepatology, Vol.72 (3), pp. 982-996.

Lampis, A. Hahne, J.C. Hedayat, S. Valeri, N. (2020). MicroRNAs as mediators of drug resistance mechanisms. Current opinion in pharmacology, Vol.54, pp. 44-50.

Acar, A. Nichol, D. Fernandez-Mateos, J. Cresswell, G.D. Barozzi, I. Hong, S.P. Trahearn, N. Spiteri, I. Stubbs, M. Burke, R. Stewart, A. Caravagna, G. Werner, B. Vlachogiannis, G. Maley, C.C. Magnani, L. Valeri, N. Banerji, U. Sottoriva, A. (2020). Exploiting evolutionary steering to induce collateral drug sensitivity in cancer. Nature communications, Vol.11 (1).

Anandappa, G. Lampis, A. Cunningham, D. Khan, K.H. Kouvelakis, K. Vlachogiannis, G. Hedayat, S. Tunariu, N. Rao, S. Watkins, D. Starling, N. Braconi, C. Darvish-Damavandi, M. Lote, H. Thomas, J. Peckitt, C. Kalaitzaki, R. Khan, N. Fotiadis, N. Rugge, M. Begum, R. Rana, I. Bryant, A. Hahne, J.C. Chau, I. Fassan, M. Valeri, N. (2019). miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial. Clinical cancer research, Vol.25 (13), pp. 3830-3838.

Fontana, E. Valeri, N. (2019). Class(y) Dissection of BRAF Heterogeneity: Beyond Non-V600. Clinical cancer research, Vol.25 (23), pp. 6896-6898.

Fassan, M. Cui, R. Gasparini, P. Mescoli, C. Guzzardo, V. Vicentini, C. Munari, G. Loupakis, F. Lonardi, S. Braconi, C. Scarpa, M. D'Angelo, E. Pucciarelli, S. Angriman, I. Agostini, M. D'Incá, R. Farinati, F. Gafà, R. Lanza, G. Frankel, W.L. Croce, C.M. Valeri, N. Rugge, M. (2019). miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. Translational oncology, Vol.12 (2), pp. 282-291.

Khan, K. Rane, J.K. Cunningham, D. Rao, S. Watkins, D. Starling, N. Kalaitzaki, E. Forster, M. Braconi, C. Valeri, N. Gerlinger, M. Chau, I. (2019). Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. Clinical colorectal cancer, Vol.18 (1), pp. 64-71.e1.

Visone, R. Bacalini, M.G. Franco, S.D. Ferracin, M. Colorito, M.L. Pagotto, S. Laprovitera, N. Licastro, D. Marco, M.D. Scavo, E. Bassi, C. Saccenti, E. Nicotra, A. Grzes, M. Garagnani, P. Laurenzi, V.D. Valeri, N. Mariani-Costantini, R. Negrini, M. Stassi, G. Veronese, A. (2019). DNA methylation of shelf, shore and open sea CpG positions distinguish high microsatellite instability from low or stable microsatellite status colon cancer stem cells. Epigenomics, Vol.11 (6), pp. 587-604.

Coati, I. Lotz, G. Fanelli, G.N. Brignola, S. Lanza, C. Cappellesso, R. Pellino, A. Pucciarelli, S. Spolverato, G. Guzzardo, V. Munari, G. Zaninotto, G. Scarpa, M. Mastracci, L. Farinati, F. Realdon, S. Pilati, P. Lonardi, S. Valeri, N. Rugge, M. Kiss, A. Loupakis, F. Fassan, M. (2019). Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. British journal of cancer, Vol.121 (3), pp. 257-263.

Salati, M. Valeri, N. Spallanzani, A. Braconi, C. Cascinu, S. (2019). Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications. European journal of surgical oncology, Vol.45 (8), pp. 1479-1482.

Pietrantonio, F. Miceli, R. Raimondi, A. Kim, Y.W. Kang, W.K. Langley, R.E. Choi, Y.Y. Kim, K.-. Nankivell, M.G. Morano, F. Wotherspoon, A. Valeri, N. Kook, M.-. An, J.Y. Grabsch, H.I. Fucà, G. Noh, S.H. Sohn, T.S. Kim, S. Di Bartolomeo, M. Cunningham, D. Lee, J. Cheong, J.-. Smyth, E.C. (2019). Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. Journal of clinical oncology, Vol.37 (35), pp. 3392-3400.  show abstract

Khan, K. Valeri, N. Dearman, C. Rao, S. Watkins, D. Starling, N. Chau, I. Cunningham, D. (2019). Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. Critical reviews in oncology/hematology, Vol.143, pp. 153-163.

Schmidt, S. Gay, D. Uthe, F.W. Denk, S. Paauwe, M. Matthes, N. Diefenbacher, M.E. Bryson, S. Warrander, F.C. Erhard, F. Ade, C.P. Baluapuri, A. Walz, S. Jackstadt, R. Ford, C. Vlachogiannis, G. Valeri, N. Otto, C. Schülein-Völk, C. Maurus, K. Schmitz, W. Knight, J.R. Wolf, E. Strathdee, D. Schulze, A. Germer, C.-. Rosenwald, A. Sansom, O.J. Eilers, M. Wiegering, A. (2019). A MYC–GCN2–eIF2α negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer. Nature cell biology, Vol.21 (11), pp. 1413-1424.

Fanelli, G.N. Loupakis, F. Smyth, E. Scarpa, M. Lonardi, S. Pucciarelli, S. Munari, G. Rugge, M. Valeri, N. Fassan, M. (2019). Pathological Tumor Regression Grade Classifications in Gastrointestinal Cancers: Role on Patients’ Prognosis. International journal of surgical pathology, Vol.27 (8), pp. 816-835.  show abstract

Valeri, N. (2019). Streamlining Detection of Fusion Genes in Colorectal Cancer: Having “Faith” in Precision Oncology in the (Tissue) “Agnostic” Era. Cancer research, Vol.79 (6), pp. 1041-1043.

Moorcraft, S.Y. Gonzalez de Castro, D. Cunningham, D. Jones, T. Walker, B.A. Peckitt, C. Yuan, L.C. Frampton, M. Begum, R. Eltahir, Z. Wotherspoon, A. Teixeira Mendes, L.S. Hulkki Wilson, S. Gillbanks, A. Baratelli, C. Fotiadis, N. Patel, A. Braconi, C. Valeri, N. Gerlinger, M. Rao, S. Watkins, D. Chau, I. Starling, N. (2018). Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice. Annals of oncology, Vol.29 (1), pp. 230-236.

Lampis, A. Carotenuto, P. Vlachogiannis, G. Cascione, L. Hedayat, S. Burke, R. Clarke, P. Bosma, E. Simbolo, M. Scarpa, A. Yu, S. Cole, R. Smyth, E. Mateos, J.F. Begum, R. Hezelova, B. Eltahir, Z. Wotherspoon, A. Fotiadis, N. Bali, M.A. Nepal, C. Khan, K. Stubbs, M. Hahne, J.C. Gasparini, P. Guzzardo, V. Croce, C.M. Eccles, S. Fassan, M. Cunningham, D. Andersen, J.B. Workman, P. Valeri, N. Braconi, C. (2018). MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology, Vol.154 (4), pp. 1066-1079.e5.

Smyth, E. Khan, K. Valeri, N. (2018). Translational research and application of basic biology to clinical trial development in GI cancers. Annals of translational medicine, Vol.6 (9), pp. 164-164.

Davarzani, N. Hutchins, G.G. West, N.P. Hewitt, L.C. Nankivell, M. Cunningham, D. Allum, W.H. Smyth, E. Valeri, N. Langley, R.E. Grabsch, H.I. (2018). Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial. Histopathology, Vol.72 (7), pp. 1180-1188.

Ghidini, M. Hahne, J.C. Frizziero, M. Tomasello, G. Trevisani, F. Lampis, A. Passalacqua, R. Valeri, N. (2018). MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours. Target oncol, Vol.13 (4), pp. 423-436.  show abstract

Sclafani, F. Chau, I. Cunningham, D. Hahne, J.C. Vlachogiannis, G. Eltahir, Z. Lampis, A. Braconi, C. Kalaitzaki, E. De Castro, D.G. Wotherspoon, A. Capdevila, J. Glimelius, B. Tarazona, N. Begum, R. Lote, H. Hulkki Wilson, S. Mentrasti, G. Brown, G. Tait, D. Oates, J. Valeri, N. (2018). KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. Scientific reports, Vol.8 (1).

Sundar, R. Miranda, S. Rodrigues, D.N. Chénard-Poirier, M. Dolling, D. Clarke, M. Figueiredo, I. Bertan, C. Yuan, W. Ferreira, A. Chistova, R. Boysen, G. Perez, D.R. Tunariu, N. Mateo, J. Wotherspoon, A. Chau, I. Cunningham, D. Valeri, N. Carreira, S. de Bono, J. (2018). Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. Clinical colorectal cancer, Vol.17 (4), pp. 280-284.

Mensah, A.A. Cascione, L. Gaudio, E. Tarantelli, C. Bomben, R. Bernasconi, E. Zito, D. Lampis, A. Hahne, J.C. Rinaldi, A. Stathis, A. Zucca, E. Kwee, I. Gattei, V. Valeri, N. Riveiro, M.E. Bertoni, F. (2018). Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma. Haematologica, Vol.103 (12), pp. 2049-2058.

Fassan, M. Vianello, L. Sacchi, D. Fanelli, G.N. Munari, G. Scarpa, M. Cappellesso, R. Loupakis, F. Lanza, C. Salmaso, R. Mescoli, C. Valeri, N. Agostini, M. D’Angelo, E. Lonardi, S. Pucciarelli, S. Veronese, N. Luchini, C. Rugge, M. (2018). Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. Cancer cell international, Vol.18 (1).

Smyth, E.C. Nyamundanda, G. Cunningham, D. Fontana, E. Ragulan, C. Tan, I.B. Lin, S.J. Wotherspoon, A. Nankivell, M. Fassan, M. Lampis, A. Hahne, J.C. Davies, A.R. Lagergren, J. Gossage, J.A. Maisey, N. Green, M. Zylstra, J.L. Allum, W.H. Langley, R.E. Tan, P. Valeri, N. Sadanandam, A. (2018). A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. Annals of oncology, Vol.29 (12), pp. 2356-2362.

Fanelli, G.N. Gasparini, P. Coati, I. Cui, R. Pakula, H. Chowdhury, B. Valeri, N. Loupakis, F. Kupcinskas, J. Cappellesso, R. Fassan, M. (2018). LONG-NONCODING RNAs in gastroesophageal cancers. Non-coding rna research, Vol.3 (4), pp. 195-212.

Lote, H. Valeri, N. Chau, I. (2018). HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer. World journal of gastrointestinal oncology, Vol.10 (7), pp. 159-171.

Smyth, E.C. Wotherspoon, A. Peckitt, C. Gonzalez, D. Hulkki-Wilson, S. Eltahir, Z. Fassan, M. Rugge, M. Valeri, N. Okines, A. Hewish, M. Allum, W. Stenning, S. Nankivell, M. Langley, R. Cunningham, D. (2017). Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. Jama oncol, Vol.3 (9), pp. 1197-1203.  show abstract

Fassan, M. Saraggi, D. Balsamo, L. Realdon, S. Scarpa, M. Castoro, C. Coati, I. Salmaso, R. Farinati, F. Guzzardo, V. Arcidiacono, D. Munari, G. Gasparini, P. Veronese, N. Luchini, C. Valeri, N. Rugge, M. (2017). Early miR-223 Upregulation in Gastroesophageal Carcinogenesis. Am j clin pathol, Vol.147 (3), pp. 301-308.  show abstract

Sundar, R. Valeri, N. Harrington, K.J. Yap, T.A. (2017). Combining Molecularly Targeted Agents: Is More Always Better?. Clinical cancer research, Vol.23 (5), pp. 1123-1125.

Saraggi, D. Fassan, M. Mescoli, C. Scarpa, M. Valeri, N. Michielan, A. D’Incá, R. Rugge, M. (2017). The molecular landscape of colitis-associated carcinogenesis. Digestive and liver disease, Vol.49 (4), pp. 326-330.

Ghidini, M. Cascione, L. Carotenuto, P. Lampis, A. Trevisani, F. Previdi, M.C. Hahne, J.C. Said-Huntingford, I. Raj, M. Zerbi, A. Mescoli, C. Cillo, U. Rugge, M. Roncalli, M. Torzilli, G. Rimassa, L. Santoro, A. Valeri, N. Fassan, M. Braconi, C. (2017). Characterisation of the immune-related transcriptome in resected biliary tract cancers. European journal of cancer, Vol.86, pp. 158-165.

Battersby, N.J. Dattani, M. Rao, S. Cunningham, D. Tait, D. Adams, R. Moran, B.J. Khakoo, S. Tekkis, P. Rasheed, S. Mirnezami, A. Quirke, P. West, N.P. Nagtegaal, I. Chong, I. Sadanandam, A. Valeri, N. Thomas, K. Frost, M. Brown, G. (2017). A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. Trials, Vol.18 (1).

Smyth, E. Zhang, S. Cunningham, D. Wotherspoon, A. Soong, R. Peckitt, C. Valeri, N. Fassan, M. Rugge, M. Okines, A. Allum, W. Stenning, S. Nankivell, M. Langley, R. Tan, P. (2017). Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy. Clinical cancer research, Vol.23 (24), pp. 7543-7549.

Tomasello, G. Valeri, N. Ghidini, M. Smyth, E.C. Liguigli, W. Toppo, L. Mattioli, R. Curti, A. Hahne, J.C. Negri, F.M. Panni, S. Ratti, M. Lazzarelli, S. Gerevini, F. Colombi, C. Panni, A. Rovatti, M. Treccani, L. Martinotti, M. Passalacqua, R. (2017). First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study. Oncotarget, Vol.8 (67), pp. 111795-111806.

Saraggi, D. Fassan, M. Bornschein, J. Farinati, F. Realdon, S. Valeri, N. Rugge, M. (2016). From Barrett metaplasia to esophageal adenocarcinoma: the molecular background. Histology and histopathology, Vol.31 (1), pp. 25-32.

Sclafani, F. Chau, I. Cunningham, D. Lampis, A. Hahne, J.C. Ghidini, M. Lote, H. Zito, D. Tabernero, J. Glimelius, B. Cervantes, A. Begum, R. De Castro, D.G. Wilson, S.H. Peckitt, C. Eltahir, Z. Wotherspoon, A. Tait, D. Brown, G. Oates, J. Braconi, C. Valeri, N. (2016). Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. Carcinogenesis, Vol.37 (9), pp. 852-857.

Smyth, E.C. Fassan, M. Cunningham, D. Allum, W.H. Okines, A.F. Lampis, A. Hahne, J.C. Rugge, M. Peckitt, C. Nankivell, M. Langley, R. Ghidini, M. Braconi, C. Wotherspoon, A. Grabsch, H.I. Valeri, N. (2016). Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. J clin oncol, Vol.34 (23), pp. 2721-2727.  show abstract

Fassan, M. Saraggi, D. Balsamo, L. Cascione, L. Castoro, C. Coati, I. De Bernard, M. Farinati, F. Guzzardo, V. Valeri, N. Zambon, C.F. Rugge, M. (2016). Let-7c down-regulation in Helicobacter pylori-related gastric carcinogenesis. Oncotarget, Vol.7 (4), pp. 4915-4924.

Sclafani, F. Chau, I. Cunningham, D. Peckitt, C. Lampis, A. Hahne, J.C. Braconi, C. Tabernero, J. Glimelius, B. Cervantes, A. Begum, R. Gonzalez De Castro, D. Hulkki Wilson, S. Eltahir, Z. Wotherspoon, A. Tait, D. Brown, G. Oates, J. Valeri, N. (2015). Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. Annals of oncology, Vol.26 (9), pp. 1936-1941.

Slattery, M.L. Herrick, J.S. Mullany, L.E. Valeri, N. Stevens, J. Caan, B.J. Samowitz, W. Wolff, R.K. (2015). An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific mortality. Int j cancer, Vol.137 (2), pp. 428-438.  show abstract

Cordero, J.B. Ridgway, R.A. Valeri, N. Nixon, C. Frame, M.C. Muller, W.J. Vidal, M. Sansom, O.J. (2014). c-Src drives intestinal regeneration and transformation. Embo j, Vol.33 (13), pp. 1474-1491.  show abstract

Ryan, B.M. Wolff, R.K. Valeri, N. Khan, M. Robinson, D. Paone, A. Bowman, E.D. Lundgreen, A. Caan, B. Potter, J. Brown, D. Croce, C. Slattery, M.L. Harris, C.C. (2014). An analysis of genetic factors related to risk of inflammatory bowel disease and colon cancer. Cancer epidemiol, Vol.38 (5), pp. 583-590.  show abstract

Valeri, N. Braconi, C. Gasparini, P. Murgia, C. Lampis, A. Paulus-Hock, V. Hart, J.R. Ueno, L. Grivennikov, S.I. Lovat, F. Paone, A. Cascione, L. Sumani, K.M. Veronese, A. Fabbri, M. Carasi, S. Alder, H. Lanza, G. Gafa', R. Moyer, M.P. Ridgway, R.A. Cordero, J. Nuovo, G.J. Frankel, W.L. Rugge, M. Fassan, M. Groden, J. Vogt, P.K. Karin, M. Sansom, O.J. Croce, C.M. (2014). MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon Cancer. Cancer cell, Vol.25 (4), pp. 469-483.

Fassan, M. Dall'Olmo, L. Galasso, M. Braconi, C. Pizzi, M. Realdon, S. Volinia, S. Valeri, N. Gasparini, P. Baffa, R. Souza, R.F. Vicentini, C. D'Angelo, E. Bornschein, J. Nuovo, G.J. Zaninotto, G. Croce, C.M. Rugge, M. (2014). Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis. Oncotarget, Vol.5 (16), pp. 7162-7171.

Valeri, N. Braconi, C. Gasparini, P. Grivennikow, S. Hart, J.R. Paone, A. Lovat, F. Fabbri, M. Gafa', R. Nuovo, G. Lanza, G. Frankel, W. Vogt, P.K. Groden, J. Karin, M. Croce, C.M. (2012). Anti-miR-135b in colon cancer treatment: Results from a preclinical study. Journal of clinical oncology, Vol.30 (4_suppl), pp. 457-457.  show abstract

Valeri, N. Braconi, C. Gasparini, P. Grivennikow, S. Hart, J.R. Paone, A. Lovat, F. Fabbri, M. Gafa', R. Nuovo, G. Lanza, G. Frankel, W. Vogt, P.K. Groden, J. Karin, M. Croce, C.M. (2012). Anti-miR-135b in colon cancer treatment: Results from a preclinical study. J clin oncol, Vol.30 (4_suppl), p. 457.  show abstract

Nuovo, G.J. Garofalo, M. Valeri, N. Roulstone, V. Volinia, S. Cohn, D.E. Phelps, M. Harrington, K.J. Vile, R. Melcher, A. Galanis, E. Sehl, S. Adair, R. Scott, K. Rose, A. Toogood, G. Coffey, M.C. (2012). Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Mod pathol, Vol.25 (10), pp. 1333-1344.  show abstract

Ryan, B.M. McClary, A.C. Valeri, N. Robinson, D. Paone, A. Bowman, E.D. Robles, A.I. Croce, C. Harris, C.C. (2012). rs4919510 in hsa-mir-608 is associated with outcome but not risk of colorectal cancer. Plos one, Vol.7 (5), p. e36306.  show abstract

Valeri, N. Gasparini, P. Braconi, C. Lovat, F. Paone, A. Fabbri, M. Nuovo, G. Fishel, R. Croce, C.M. (2011). Effect of miR-21 on resistance to 5-fluorouracil and regulation of MSH2. Journal of clinical oncology, Vol.29 (4_suppl), pp. 431-431.  show abstract

Braconi, C. Kogure, T. Valeri, N. Gasparini, P. Huang, N. Nuovo, G. Terracciano, L. Croce, C.M. Patel, T. (2011). Effect of the ultraconserved noncoding RNA uc 338 on cellular growth of hepatocarcinoma. Journal of clinical oncology, Vol.29 (4_suppl), pp. 202-202.  show abstract

Voltan, R. di Iasio, M.G. Bosco, R. Valeri, N. Pekarski, Y. Tiribelli, M. Secchiero, P. Zauli, G. (2011). Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells. Clin cancer res, Vol.17 (17), pp. 5649-5655.  show abstract

Valeri, N. Gasparini, P. Braconi, C. Lovat, F. Paone, A. Fabbri, M. Nuovo, G. Fishel, R. Croce, C.M. (2011). Effect of miR-21 on resistance to 5-fluorouracil and regulation of MSH2. J clin oncol, Vol.29 (4_suppl), p. 431.  show abstract

Braconi, C. Kogure, T. Valeri, N. Gasparini, P. Huang, N. Nuovo, G. Terracciano, L. Croce, C.M. Patel, T. (2011). Effect of the ultraconserved noncoding RNA uc 338 on cellular growth of hepatocarcinoma. J clin oncol, Vol.29 (4_suppl), p. 202.  show abstract

Fabbri, M. Bottoni, A. Shimizu, M. Spizzo, R. Nicoloso, M.S. Rossi, S. Barbarotto, E. Cimmino, A. Adair, B. Wojcik, S.E. Valeri, N. Calore, F. Sampath, D. Fanini, F. Vannini, I. Musuraca, G. Dell'Aquila, M. Alder, H. Davuluri, R.V. Rassenti, L.Z. Negrini, M. Nakamura, T. Amadori, D. Kay, N.E. Rai, K.R. Keating, M.J. Kipps, T.J. Calin, G.A. Croce, C.M. (2011). Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. Jama, Vol.305 (1), pp. 59-67.  show abstract

Braconi, C. Valeri, N. Kogure, T. Gasparini, P. Huang, N. Nuovo, G.J. Terracciano, L. Croce, C.M. Patel, T. (2011). Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc natl acad sci u s a, Vol.108 (2), pp. 786-791.  show abstract

Lovat, F. Valeri, N. Croce, C.M. (2011). MicroRNAs in the pathogenesis of cancer. Semin oncol, Vol.38 (6), pp. 724-733.  show abstract

Braconi, C. Kogure, T. Valeri, N. Nuovo, G. Costinean, S. Croce, C.M. Patel, T. (2011). Abstract 1178: Involvement of MEG3, a long non-coding RNA, in hepatocellular cancer (HCC). Cellular and molecular biology, .

Braconi, C. Kogure, T. Valeri, N. Huang, N. Nuovo, G. Costinean, S. Negrini, M. Miotto, E. Croce, C.M. Patel, T. (2011). microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene, Vol.30 (47), pp. 4750-4756.  show abstract

Braconi, C. Valeri, N. Gasparini, P. Huang, N. Taccioli, C. Nuovo, G. Suzuki, T. Croce, C.M. Patel, T. (2010). Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin cancer res, Vol.16 (3), pp. 957-966.  show abstract

Braconi, C. Kogure, T. Valeri, N. Huang, N. Gasparini, P. Nuovo, G. Terracciano, L. Croce, C.M. Patel, T. (2010). Ultraconserved non-coding RNAs are involved in human hepatocellular cancer growth. Cancer research, Vol.70.

Cohn, D.E. Fabbri, M. Valeri, N. Alder, H. Ivanov, I. Liu, C.-. Croce, C.M. Resnick, K.E. (2010). Comprehensive miRNA profiling of surgically staged endometrial cancer. Am j obstet gynecol, Vol.202 (6), pp. 656.e1-656.e8.  show abstract

Valeri, N. Gasparini, P. Braconi, C. Paone, A. Lovat, F. Fabbri, M. Sumani, K.M. Alder, H. Amadori, D. Patel, T. Nuovo, G.J. Fishel, R. Croce, C.M. (2010). MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc natl acad sci u s a, Vol.107 (49), pp. 21098-21103.  show abstract

Valeri, N. Gasparini, P. Fabbri, M. Braconi, C. Veronese, A. Lovat, F. Adair, B. Vannini, I. Fanini, F. Bottoni, A. Costinean, S. Sandhu, S.K. Nuovo, G.J. Alder, H. Gafa, R. Calore, F. Ferracin, M. Lanza, G. Volinia, S. Negrini, M. McIlhatton, M.A. Amadori, D. Fishel, R. Croce, C.M. (2010). Modulation of mismatch repair and genomic stability by miR-155. Proc natl acad sci u s a, Vol.107 (15), pp. 6982-6987.  show abstract

Braconi, C. Kogure, T. Valeri, N. Huang, N. Gasparini, P. Nuovo, G. Terracciano, L. Croce, C.M. Patel, T. (2010). Abstract 4086: Ultraconserved non-coding RNAs are involved in human hepatocellular cancer growth. Cellular and molecular biology, .

Fabbri, M. Adair, B. Wernicke, D. Garzon, R. Valeri, N. Cimmino, A. Zanesi, N. Croce, C. (2009). MicroRNA 29 family restores estrogen receptor and selective estrogen receptors regulators (SERMs) sensitivity in breast cancer. Cancer research, Vol.69.

Fabbri, M. Valeri, N. Calin, G.A. (2009). MicroRNAs and genomic variations: from Proteus tricks to Prometheus gift. Carcinogenesis, Vol.30 (6), pp. 912-917.  show abstract

Valeri, N. Croce, C.M. Fabbri, M. (2009). Pathogenetic and clinical relevance of microRNAs in colorectal cancer. Cancer genomics proteomics, Vol.6 (4), pp. 195-204.  show abstract

Valeri, N. Vannini, I. Fanini, F. Calore, F. Adair, B. Fabbri, M. (2009). Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mamm genome, Vol.20 (9-10), pp. 573-580.  show abstract

Resnick, K.E. Fabbri, M. Valeri, N. Alder, H. Taccioli, C. Liu, C.-. Cohn, D.E. Croce, C.M. (2008). MiRNA profile in stage 1, surgically staged endometrial cancer and predicted downstream targets. Gynecologic oncology, Vol.108 (3), pp. S11-S11.

Braconi, C. Bracci, R. Bearzi, I. Bianchi, F. Costagliola, A. Catalani, R. Mandolesi, A. Ranaldi, R. Galizia, E. Cascinu, S. Rossi, G. Giustini, L. Latini, L. Valeri, N. Cellerino, R. (2008). KIT and PDGFRalpha mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study. Ann oncol, Vol.19 (4), pp. 706-710.  show abstract

Braconi, C. Bracci, R. Bearzi, I. Bianchi, F. Sabato, S. Mandolesi, A. Belvederesi, L. Cascinu, S. Valeri, N. Cellerino, R. (2008). Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann oncol, Vol.19 (7), pp. 1293-1298.  show abstract

Cascinu, S. Verdecchia, L. Valeri, N. Berardi, R. Scartozzi, M. (2006). New target therapies in advanced pancreatic cancer. Ann oncol, Vol.17 Suppl 5, pp. v148-v152.  show abstract

Valeri, N. Battelli, N. Mariotti, C. Santinelli, A. Siquini, W. Gusella, P. Braconi, C. Lippe, P. Cascinu Prof, S. (2006). CEA as a prognostic factor in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy. J clin oncol, Vol.24 (18_suppl), p. 10705.  show abstract

Khan, K. Rata, M. Cunningham, D. Koh, D.M. Tunariu, N. Hahne, J.C. Vlachogiannis, G. Hedayat, S. Marchetti, S. Lampis, A. Darvish Damavandi, M. Lote, H. Williams, A. Eccles, S.A. Fontana, E. Collins, D. Eltahir, Z. Rao, S. Watkins, D. Starling, N. Thomas, J. Kalaitzaki, E. Fotiadis, N. Begum, R. Bali, M. Rugge, M. Temple, E. Fassan, M. Chau, I. Braconi, C. Valeri, N. Functional Imaging and circulating biomarkers of response to Regorafenib in treatment-refractory metastatic colorectal cancer patients in a PROSPECTive phase II study (PROSPECT-R). Gut, .

Vlachogiannis, G. Hedayat, S. Vatsiou, A. Jamin, Y. Fernandez Mateos, J. Khan, K. Lampis, A. Eason, K. Burke, R. Rata, M. Koh, D.-. Tunariu, N. Collins, D. Hulkki, S. Ragulan, C. Spiteri Sagastume, I. Moorcraft, S.Y. Chau, I. Rao, S. Watkins, D. Fotiadis, N. Bali, M. Darvish Damavandi, M. Lote, H. Eltahir, Z. Smyth, L. Begum, R. Clarke, P. Hahne, J. Dowsett, M. De Bono, J. Workman, P. Sadanandam, A. Eccles, S. Starling, N. Braconi, C. Sottoriva, A. Robinson, S. Cunningham, D. Valeri, N. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, .

Hahne, J. Valeri, N. Non-coding RNAs and resistance to anticancer drugs in gastrointestinal tumours. Frontiers of oncology, .

Hahne, J. Ratti, M. Lampis, A. Passalacquab, R. Valeri, N. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives and new treatment approaches. Cellular and molecular life sciences, .

Khan, K. Cunningham, D. Werner, B. Vlachogiannis, G. Spiteri Sagastume, I. Heide, T. Fernandez Mateos, J. Vatsiou, A. Lampis, A. Damavandi, M.D. Lote, H. Huntingford, I.S. Hedayat, S. Chau, I. Tunariu, N. Mentrasti, G. Trevisani, F. Rao, S. Anandappa, G. Watkins, D. Starling, N. Thomas, J. Peckitt, C. Khan, N. Rugge, M. Begum, R. Hezelova, B. Bryant, A. Jones, T. Proszek, P. Fassan, M. Hahne, J. Hubank, M. Braconi, C. Sottoriva, A. Valeri, N. Longitudinal liquid biopsy and mathematical modelling of clonal evolution forecast waiting time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. Cancer discovery, .

Wagner, S. Vlachogiannis, G. De Haven Brandon, A. Valenti, M. Box, G. Jenkins, L. Mancusi, C. Self, A. Manodoro, F. Assiotis, I. Robinson, P. Chauhan, R. Rust, A. Matthews, N. Eason, K. Khan, K. Starling, N. Cunningham, D. Sadanandam, A. Isacke, C. Kirkin, V. Valeri, N. Whittaker, S. Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. Oncogene, .

Lote, H. Spiteri Sagastume, I. Ermini, L. Vatsiou, A. Roy, A. McDonald, A. Maka, N. Balsitis, M. Bose, N. Simbolo, M. Mafficini, A. Lampis, A. hahne, J. Trevisani, F. Eltahir, Z. Mentrasti, G. Findlay, C. Kalkman, E. Punta, M. Werner, B. Lise, S. Aktipis, A. Maley, C. Greaves, M. Braconi, C. White, J. Fassan, M. Scarpa, A. Sottoriva, A. Valeri, N. Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer. Annals of oncology, .

Trevisani, F. Ghidini, M. Larcher, A. Lampis, A. Lote, H. Manunta, P. Sciarrone Alibrandi, M.T. Zagato, L. Citterio, L. Dell’Antonio, G. Carenzi, C. Capasso, G. Rugge, M. Rigotti9, P. Bertini, R. Cascione, L. Briganti, A. Salonia, A. Benigni, F. Braconi, C. Fassan, M. Hahne, J.C. Montorsi, F. Valeri, N. MicroRNA 193b-3p as a Predictive Biomarker of Chronic Kidney Disease in Patients Undergoing Radical Nephrectomy for Renal Cell Carcinoma. British journal of cancer, .

Carotenuto, P. Braconi, C. Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. Gut, .

Smyth, E.C. Vlachogiannis, G. Hedayat, S. Harbery, A. Hulkki-Wilson, S. Salati, M. Kouvelakis, K. Fernandez-Mateos, J. Cresswell, G.D. Fontana, E. Seidlitz, T. Peckitt, C. Hahne, J.C. Lampis, A. Begum, R. Watkins, D. Rao, S. Starling, N. Waddell, T. Okines, A. Crosby, T. Mansoor, W. Wadsley, J. Middleton, G. Fassan, M. Wotherspoon, A. Braconi, C. Chau, I. Vivanco, I. Sottoriva, A. Stange, D.E. Cunningham, D. Valeri, N. EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. Gut, .  show abstract

Zaniboni, A. Ghidini, M. Grossi, F. Indini, A. Trevisan, F. Iaculli, A. Dottorini, L. Moleri, G. Russo, A. Vavassori, I. Brevi, A. Rausa, E. Boni, L. Dondossola, D. Valeri, N. Ghidini, A. Tomasello, G. Petrelli, F. A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic. Cancers, Vol.12 (9), pp. 2452-2452.  show abstract

Khan, K. Gonzalez-Exposito, R. Cunningham, D. Koh, D.-. Woolston, A. Barber, L. Griffiths, B. Kouvelakis, K. Calamai, V. Bali, M. Khan, N. Bryant, A. Saffery, C. Dearman, C. Begum, R. Rao, S. Starling, N. Watkins, D. Chau, I. Braconi, C. Valeri, N. Gerlinger, M. Fotiadis, N. Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data. Frontiers in oncology, Vol.10.

Hahne, J.C. Lampis, A. Valeri, N. Vault RNAs: hidden gems in RNA and protein regulation. Cellular and molecular life sciences, .  show abstract

Knight, J.R. Alexandrou, C. Skalka, G.L. Vlahov, N. Pennel, K. Officer, L. Teodosio, A. Kanellos, G. Gay, D.M. May-Wilson, S. Smith, E.M. Najumudeen, A.K. Gilroy, K. Ridgway, R.A. Flanagan, D.J. Smith, R.C. McDonald, L. MacKay, C. Cheasty, A. McArthur, K. Stanway, E. Leach, J.D. Jackstadt, R. Waldron, J.A. Campbell, A.D. Vlachogiannis, G. Valeri, N. Haigis, K.M. Sonenberg, N. Proud, C.G. Jones, N.P. Swarbrick, M.E. McKinnon, H.J. Faller, W.J. Le Quesne, J. Edwards, J. Willis, A.E. Bushell, M. Sansom, O.J. MNK inhibition sensitizes KRAS-mutant colorectal cancer to mTORC1 inhibition by reducing eIF4E phosphorylation and c-MYC expression. Cancer discovery, .

Ghidini, M. Lampis, A. Mirchev, M.B. Okuducu, A.F. Ratti, M. Valeri, N. Hahne, J.C. Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. Genes, Vol.12 (1), pp. 33-33.  show abstract

Book Chapters

Hahne, J. Honig, A. Engel, J.B. Lampis, A. Valeri, N. Analysing Molecular Mechanism Related to Therapy-Resistance in In-vitro Models of Ovarian Cancer. .


Smyth, E.C.Kouvelakis, K.Cunningham, D.Peckitt, C.Nankivell, M.G.Allum, W.H.Wotherspoon, A.Hahne, J.Lampis, A.Langley, R.E.Valeri, N. (2018). Single nucleotide polymorphisms of mir-608, LCS-6, and overall survival in the MAGIC trial., Journal of Clinical Oncology, Vol.36 (4_suppl), p.58.

Carotenuto, P.Zito, D.Previdi, M.C.Raj, M.Fassan, M.Lampis, A.Scalafani, F.Lanese, A.Said-Huntingford, I.Hahne, J.C.Young, K.Begum, R.Ethiar, Z.Wotherspoon, A.Starling, N.Sadanandam, A.Cunningham, D.Chau, I.Workman, P.Chopra, R.Valeri, N.Braconi, C. (2018). Abstract 4977: MIR1307 mediates pancreatic cancer resistance to FOLFIRINOX chemotherapy by affecting response to DNA damage, Presented at Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL, Molecular and Cellular Biology / Genetics, .

Wagner, S.Vlachogiannis, G.Brandon, A.D.Valenti, M.Box, G.Jenkins, L.Mancusi, C.Self, A.Chauhan, R.Rust, A.Matthews, N.Eason, K.Sadanandam, A.Isacke, C.Kirkin, V.Valeri, N.Whittaker, S.R. (2018). Abstract LB-094: Suppression of inflammatory gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer, Presented at Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL, Experimental and Molecular Therapeutics, .

Smyth, E.Kouvelakis, K.Cunningham, D.Hahne, J.C.Peckitt, C.Vlachogiannis, G.Watkins, D.Rao, S.Starling, N.Wilson, S.H.Waddell, T.S.Okines, A.Crosby, T.Mansoor, W.Wadsley, J.Middleton, G.Wotherspoon, A.Chau, I.Valeri, N. (2018). EGFR amplification (amp) and survival in the REAL-3 trial, Annals of Oncology, Vol.29, p.viii217.

Kuhnl, A.Peckitt, C.Patel, B.Ardeshna, K.M.Macheta, M.P.Radford, J.Johnson, R.Paneesha, S.Barton, S.Chau, I.Kaiser, M.F.Begum, R.Valeri, N.Wotherspoon, A.Du, Y.Zerizer, I.Cunningham, D. (2017). R-GEM-Lenalidomide Versus R-GEM-P As Second-Line Treatment of Diffuse Large B-Cell Lymphoma: Results from the UK NCRI Phase II Randomized Legend Trial, BLOOD, Vol.130.

Sclafani, F.Gollins, S.Cunningham, D.Wilson, S.H.Kouvelakis, K.Lopes, A.West, N.Quirke, P.Begum, R.Valeri, N.Beare, S.Hughes, L.De Castro, D.G.Chau, I. (2017). FC gamma RIIa and FC gamma RIIIa single nucleotide polymorphisms (SNPs) and cetuximab benefit in the EXCITE trial, ANNALS OF ONCOLOGY, Vol.28.

Khan, K.H.Rata, M.Koh, D.-.Tunariu, N.Collins, D.J.Chau, I.Watkins, D.J.Starling, N.Rao, S.Peckitt, C.Fotiadis, N.Begum, R.Saffery, C.Thomas, J.Gerlinger, M.Valeri, N.Cunningham, D. (2016). A prospective translational study investigating molecular predictors of resistance and response to regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (mCRC): Initial magnetic resonance imaging (MRI) sub-study result., Journal of Clinical Oncology, Vol.34 (4_suppl), p.580.

Khan, K.Vlachogianis, G.Cunningham, D.Hahne, J.Darvish-Damavandi, M.Barton, S.Trevisani, F.Mentrast, G.Peckitt, C.Lampis, A.Braconi, C.Khan, N.Begum, R.Starling, N.Rao, S.Watkins, D.Bryant, A.Chau, I.Valeri, N. (2015). Abstract 3589: Validation of the role of circulating tumor DNA (ctDNA) in tracking mechanisms of resistance to anti-EGFR monoclonal antibodies (AE-mABs): preliminary results of the PROSPECT-C prospective trial, Presented at Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA, Experimental and Molecular Therapeutics, .

Darvish Damavandi, M.Braconi, C.Cascione, L.Lampis, A.Hahne, J.Murgia, C.Ghidini, M.Nyamundanda, G.Sadanandam, A.Croce, C.Sansom, O.Valeri, N. (2015). Abstract 3083: Global gene expression profiling of mice tumor-derived organoids identifies key microRNAs and metabolic genes involved in CRC progression, Presented at Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA, Molecular and Cellular Biology, .

Cheong, I.H.Lampis, A.Fassan, M.Paulus-Hock, V.Vicentini, C.Hahne, J.Cascione, L.Quagliata, L.Jamieson, T.Athineos, D.Veronese, A.Visone, R.Murgia, C.Ferrari, G.Evans, T.R.Feng, G.J.Dale, T.Boulter, L.Guest, R.Forbes, S.Negrini, M.Terracciano, L.Scarpa, A.Patel, T.Workman, P.Sansom, O.Valeri, N.Braconi, C. (2015). P0282 : The long non coding RNA UC.158 modulates growth of Wnt/β;-catenin driven hepatocellular carcinoma (HCC), Journal of Hepatology, Vol.62, pp.S413-S414.

Trevisani, F.Ghidini, M.Manunta, P.Hahne, J.Lampis, A.Braconi, C.Sciarrone Alibrandi, M.T.Zagato, L.Cittero, L.Dell'antonio, G.Bertini, R.Salonia, A.Benigni, F.Capasso, G.Rigatti, P.Cestari, A.Rugge, M.Fassan, M.Valeri, N. (2015). SP299MICRORNA-200B AS PREDICTIVE BIOMARKER OF CHRONIC KIDNEY DISEASE (CKD) IN PATIENTS UNDERGOING RADICAL NEPHRECTOMY, Nephrology Dialysis Transplantation, Vol.30 (suppl_3), p.iii478.

Khan, K.Chau, I.Gerlinger, M.Valeri, N.Koh, D.-.Starling, N.Watkins, D.Rao, S.Tunariu, N.Fotiadis, N.Begum, R.Saffery, C.Cunningham, D. (2015). P-309 PROSPECT-R: A PROSPECTive translational study investigating molecular predictors of resistance and response to Regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (CRC), Annals of Oncology, Vol.26, p.iv91.

Sclafani, F.Chau, I.Cunningham, D.Peckitt, C.Lampis, A.Hahne, J.C.Braconi, C.Tabernero, J.Glimelius, B.Cervantes, A.Begum, R.Castro, D.G.Hulkki Wilson, S.Eltahir, Z.Wotherspoon, A.Tait, D.Brown, G.Oates, J.Valeri, N. (2015). 2188 Prognostic role of the LCS-6 KRAS variant in locally advanced rectal cancer: Results of the EXPERT-C trial, European Journal of Cancer, Vol.51, p.S396.

Ghidini, M.Trevisani, F.Fassan, M.Cascione, L.Hahne, J.C.Lampis, A.Cheong, I.H.Scarpa, A.Vicentini, C.Zerbi, A.Torzilli, G.Roncalli, M.Rimassa, L.Valeri, N.Santoro, A.Braconi, C. (2015). Retrospective analysis of the role of adjuvant chemotherapy and microRNAs expression in resected cholangiocarcinomas (CCAs), ANNALS OF ONCOLOGY, Vol.26, p.97.

Sclafani, F.Chau, I.Cunningham, D.Lampis, A.Hahne, J.Braconi, C.Peckitt, C.Gonzalez, D.Hullki Wilson, S.Capdevila, J.Glimelius, B.Cervantes, A.Begum, R.Brown, G.Tait, D.M.Wotherspoon, A.Eltahir, Z.Yusuf-Adam, S.Oates, J.R.Valeri, N. (2015). Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial., Journal of Clinical Oncology, Vol.33 (3_suppl), p.581.

Moorcraft, S.Y.Gonzalez de Castro, D.Cunningham, D.Walker, B.A.Hulkki Wilson, S.Diez Perez, J.Peckitt, C.Wotherspoon, A.Begum, R.Valeri, N.Gerlinger, M.Braconi, C.Rao, S.Watkins, D.Chau, I.Starling, N. (2015). FOrMAT: Feasibility of a molecular characterization approach to treatment of patients (pts) with advanced gastrointestinal (GI) tumors., Journal of Clinical Oncology, Vol.33 (3_suppl), p.TPS227.

Paulus-Hock, V.Lampis, A.Ferrari, G.Boulton, L.Guest, R.Athineos, D.Jamieson, T.Veronese, A.Visone, R.Evans, R.Feng, G.J.Dale, T.Negrini, M.Forbes, S.Patel, T.Sansom, O.Valeri, N.Braconi, C. (2014). P64 THE ULTRACONSERVED NON CODING RNA UC.158 IS DOWNSTREAM OF THE WNT/b-CATENIN PATHWAY IN LIVER CANCERS, Journal of Hepatology, Vol.60 (1), p.S88.

Braconi, C.Valeri, N.Gasparini, P.Jiang, J.Kogure, T.Croce, C.Schmittgen, T.Patel, T. (2013). Transcribed ultraconserved regions are aberrantly expressed and can be modulated by interleukin 6 in cholangiocarcinoma, LANCET, Vol.381, p.26.

Valeri, N.Braconi, C.Gasparini, P.Hart, J.Grivennikov, S.Lovat, F.Lanza, G.Gafa, R.Nuovo, G.Frankel, W.Groden, J.Vogt, P.K.Karin, M.Croce, C.M. (2013). microRNA-135b promotes cancer progression acting as a downstream effector of oncogenic pathways in colon cancer, LANCET, Vol.381, p.17.

Patents and patent applications

Ghidini, M.Hahne, J.C.Senti, C.Lampis, A.Ratti, M.Pizzo, C.Tomasello, G.Passalacqua, R.Valeri, N. (2019). Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease.

Hutchins, G.G.Davarzani, N.West, N.P.Hewitt, L.Nankivell, M.Cunningham, D.Allum, W.H.Smyth, E.Valeri, N.Langley, R.E.Grabsch, H.I. (2018). Defining the Clinical Value of Pathological Lymph Node Status and Primary Tumour Regression Grading Following Neoadjuvant Therapy in Oesophageal Cancer: Results from the MRC OE02 Trial.

Valeri, N.Croce, C.M. Materials and Methods Related to Modulation of Mismatch Repair and Genomic Stability by miR-155.